Status:
COMPLETED
Intra-individual Comparison of Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses
Lead Sponsor:
Galderma R&D
Conditions:
Actinic Keratoses
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main objective of this study is to compare efficacy and safety of Metvix® natural daylight photodynamic therapy with those of Metvix® conventional photodynamic therapy with Aktilite™ lamp in subje...
Eligibility Criteria
Inclusion
- Male or female above 18 years;
- Subject with clinical diagnosis of mild AK on the face or the scalp with or without clinical diagnosis of moderate AK on the target areas (TAs);
Exclusion
- Subject with clinical diagnosis of at least one severe AK on TAs
- Subject with clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the TAs;
- Subject with pigmented AK on the TAs
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01475071
Start Date
March 1 2012
End Date
March 1 2013
Last Update
February 18 2021
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Galderma Investigational site
Phillip, Australian Capital Territory, Australia
2
Galderma Investigational Site
Kogarah, New South Wales, Australia
3
Galderma Investigational site
Sydney, New South Wales, Australia
4
Galderma Investigational site
Westmead, New South Wales, Australia